<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226340</url>
  </required_header>
  <id_info>
    <org_study_id>HL_LDN_504</org_study_id>
    <nct_id>NCT03226340</nct_id>
  </id_info>
  <brief_title>S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and&#xD;
      S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled&#xD;
      With CCB(Calcium Channel Blocker) Monotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to verify the difference at week 12 from the baseline value in the&#xD;
      average variation of diastolic blood pressure (sitDBP) of the study group in which&#xD;
      S-amlodipine / Chlorthalidone combination therapy is to be used in patients with essential&#xD;
      hypertension who did not adequately respond to monotherapy of amlodipine or S-amlodipine,&#xD;
      compared to the control group, in which a combination therapy of S-amlodipine / telmisartan&#xD;
      is to be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sit diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in sit diastolic blood pressure after 12 weeks compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sit diastolic blood pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean change in sit diastolic blood pressure after 6 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sit systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in sit systolic blood pressure after 6 weeks and 12 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure normalization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure normalization ratio after 12 weeks compared to baseline( sit systolic blood pressure &lt;140 mmHg or sit diastolic blood pressure &lt;90 mmHg).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>S-amlodipine + Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-amlodipine + Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 2.5mg + Chlorthalidone 25mg</intervention_name>
    <description>patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.</description>
    <arm_group_label>S-amlodipine + Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 2.5mg + Telmisartan 40mg</intervention_name>
    <description>patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.</description>
    <arm_group_label>S-amlodipine + Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women with essential hypertension who were aged 19 years or older and younger&#xD;
             than 80 years&#xD;
&#xD;
          2. Patients who have been treated with amlodipine or S-amlodipine monotherapy for more&#xD;
             than 2 weeks immediately before visit 1 (screening)&#xD;
&#xD;
          3. Visit 1 (screening) reference mean blood pressure measured three times in the arm is&#xD;
             greater than sit DBP 90 mmHg&#xD;
&#xD;
          4. Those who have voluntarily agreed in writing to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of secondary hypertension and all those with suspected&#xD;
             secondary hypertension (including, but not limited to, coarctation of the aorta,&#xD;
             primary aldosteronism, renal artery stenosis, Cushing's syndrome, chromium-rich cell&#xD;
             tumor, polycystic kidney disease, etc.)&#xD;
&#xD;
          2. Patients with a mean SBP of 200 mmHg or more or a sit DBP of 110 mmHg or more at visit&#xD;
             1.&#xD;
&#xD;
          3. When the blood pressure was measured three times in the reference arm of visit 1&#xD;
             (screening), the difference between the highest lowest sit SBP was 20 mmHg or higher&#xD;
             and the difference between the highest lowest sit DBP was 10 mmHg or higher.&#xD;
&#xD;
          4. An uncontrolled diabetic patient(HbA1c≥9.0%)&#xD;
&#xD;
          5. In addition to antihypertensive drugs, drugs that may affect blood pressure( Systemic&#xD;
             steroids, Thyroid hormones, Oral contraceptives, antipsychotic drugs, NSAIDs,&#xD;
             sympathomimetics, immunosuppressants, etc.) have been continuously administered for&#xD;
             more than 12 weeks prior to visit 1 (screening)&#xD;
&#xD;
          6. Patients who are expected to take antihypertensive drugs other than clinical drugs&#xD;
             during the trial&#xD;
&#xD;
          7. Patients with orthostatic hypotension with symptoms&#xD;
&#xD;
          8. Patients with a history of malignant tumors including leukemia and lymphoma within the&#xD;
             past 5 years&#xD;
&#xD;
          9. Patients with a history of autoimmune diseases such as chronic joint rheumatism and&#xD;
             systemic lupus erythematosus&#xD;
&#xD;
         10. Those who have a history of hypersensitivity to the amlodipine nicotinate or other&#xD;
             chlortalidone or telmisartan drug&#xD;
&#xD;
         11. Patients with clinically significant renal • hepatic disease such as those on&#xD;
             dialysis, cirrhosis, biliary obstruction, hepatic failure, or those who have the&#xD;
             following findings on visit 1 (screening)&#xD;
&#xD;
               -  ALanine Transaminase or ASpartate Transaminase is more than 3 times the normal&#xD;
                  upper limit&#xD;
&#xD;
               -  Total bilirubin more than twice the normal upper limit&#xD;
&#xD;
               -  More than twice the Blood Urea Nitrogen normal upper limit&#xD;
&#xD;
               -  Alkaline Phosphatase More than twice the normal upper limit - Creatinine&#xD;
                  Clearance Less than 10 mL / min&#xD;
&#xD;
         12. Within the last 6 months, patients who have received the following diseases or&#xD;
             treatments and whose clinical judgment is meaningful to the researcher&#xD;
&#xD;
               -  Severe heart disease (heart failure New York Heart Association class III and IV),&#xD;
                  ischemic heart disease, peripheral vascular disease, hemodynamically significant&#xD;
                  valve stenosis, arrhythmia, etc&#xD;
&#xD;
               -  Patients with severe cerebrovascular disorders (stroke, cerebral infarction,&#xD;
                  cerebral hemorrhage, etc.)&#xD;
&#xD;
         13. Shock patient&#xD;
&#xD;
         14. Patients with clinical history of alcohol or substance abuse&#xD;
&#xD;
         15. Patients with potential pregnancy or breastfeeding&#xD;
&#xD;
               -  In the case of pregnant women, if the negative is not confirmed during pregnancy&#xD;
                  test&#xD;
&#xD;
               -  Women who did not consent to contraception in a medically acceptable way during&#xD;
                  the trial&#xD;
&#xD;
               -  Medically acceptable contraceptive methods: use condoms, injectable or injectable&#xD;
                  contraceptives, intrauterine contraceptive device, etc.&#xD;
&#xD;
         16. If the tester judges that the participation in the clinical trial is not legal or&#xD;
             mental character&#xD;
&#xD;
         17. Clinical studies with other clinical trial drugs within 4 weeks prior to screening&#xD;
             patients with experience&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <state>Dongan-gu</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Ho Jo</last_name>
      <phone>82-31-380-3722</phone>
      <email>sophi5neo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Joong Kim</last_name>
      <phone>82-2-958-8180</phone>
      <email>soojoong@dreamwiz.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangdong-gu,</state>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoo-Rok Han</last_name>
      <phone>82-2-2224-2405</phone>
      <email>krheart@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Ji Park</last_name>
      <phone>82-2-3410-0887</phone>
      <email>tyche.park@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Univ. Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eung-ju Kim, MD,PhD</last_name>
      <phone>82-8-2626-3022</phone>
      <email>withnoel@empas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Jai Cho</last_name>
      <phone>82-2-2072-3931</phone>
      <email>hyunjaicho@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seongdong-gu</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ho Shin</last_name>
      <phone>82-2-2290-8308</phone>
      <email>jhs2003@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Min Song</last_name>
      <phone>82-2-3010-3158</phone>
      <email>jmsong@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou Univ. Medical Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Yeong-tong</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon-han Shin, MD,PhD</last_name>
      <phone>82-31-219-5710</phone>
      <email>shinjh@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Ju Choi, MD, PhD</last_name>
      <phone>82-31-787-7007</phone>
      <email>djchoi@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Jin Joo Park, MD</last_name>
      <phone>82-31-787</phone>
      <phone_ext>7074</phone_ext>
      <email>jinjooparkmd@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

